Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims largely align with the label on embryo-fetal risk, pregnancy-related counseling, contraception requirements, and registry reporting. Several statements are mischaracterized or not supported by the label (notably total litter loss in rabbits, FDA risk-category wording, and fertility implications). There are notable omissions (pediatric use 8.4, boxed warnings, hepatic-impairment dosing guidance, and explicit pregnancy registry/contact details) that limit safe and complete representation.
Category Scores
Accurate Statements
Lurbinectedin can cause fetal harm based on animal data and its mechanism of action.
5.5, 12.1
There are no available data to inform the risk of ZEPZELCA use in pregnant women.
8.1
Pregnancy should be verified prior to initiating treatment for females of reproductive potential.
8.1
Female patients should use effective contraception during treatment and for 7 months after the last dose.
8.3
Male patients with a female reproductive partner should use effective contraception during treatment and for 4 months after the last dose.
8.3
There is a pregnancy exposure registry and FDA MedWatch reporting for exposure during pregnancy.
8.1
Do not breastfeed during treatment and for 2 weeks after last dose.
8.2
Unsupported Statements
Rabbits showed total litter loss at all doses tested.
Not described in label sections (8.1/5.5); label discusses embryolethality in rats and general fetal harm concepts.
There is no specific antidote; report to Zepzelca Pregnancy Exposure Registry (1-888-438-4239) or FDA MedWatch for monitoring.
Antidote language is not present in the provided label sections; registry/MedWatch reporting is mentioned, but not as an antidote statement.
Male-mediated effects: Unknown risk to partner pregnancies from semen.
Paternal/semen-related risk statements are not explicitly described in the provided label content.
Fertility preservation: Consider options before starting, as ovarian function may be impaired.
Fertility preservation guidance is not clearly stated in the reproductive-potential sections that are provided.
Contradictions
Low
AI Statement
Women of reproductive potential must use effective contraception during treatment and for 6 months after the last dose.
Label Reference
8.3
Important Omissions
Pediatric safety information (8.4) is not addressed.
Importance:
Moderate
Boxed warnings and explicit contraindications (hematologic/hepatotoxicity) are not reflected in category scores.
Importance:
High
Dosing safety details and hepatic impairment dose modifications (label sections 2.1, 2.2) are not incorporated.
Importance:
Moderate
Explicit pregnancy registry and MedWatch contact details are not clearly cited in the evaluation.
Importance:
Moderate
Precise contraception duration by sex (women 7 months, men 4 months) and verification wording in label (8.3) should be consistently applied.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Risk is primarily associated with pregnancy exposure and contraception requirements; in non-pregnant individuals the label emphasizes precaution rather than acute high-risk events.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Misstatements about animal findings (e.g., total litter loss in rabbits) and incorrect explicit risk-category wording; omissions of pediatric use (8.4), boxed warnings, hepatic-dose modifications, and precise registry details.
Suggested Improvement
Correct misstatements to align with label language; include pediatric use information (8.4), boxed warnings, contraindications, hepatic impairment dosing guidance (2.1/2.2), and confirm pregnancy registry/MedWatch contact details; ensure contraception durations by sex match label (7 months for females, 4 months for males) and rephrase paternal exposure guidance to reflect exact label language.